Ackman Shoots Down Idea of Valeant (VRX) Unloading Bausch & Lomb
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Valeant (VRX) Divestitures 'Unlikely' Near-Term, Says Rodman & Renshaw
April 11, 2016 8:21 AM EDTRodman & Renshaw reiterated a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with an updated price target of $105.00 (prior $118.00). The change reflects higher interest expense.
Analyst Raghuram Selvaraju also said he thinks near-term divestitures are unlikely. Comments follow rumors it would seek a sale of core assets like Bausch + Lomb.
"From our perspective, it is unlikely that Valeant would seek to sell core assets such as the Bausch + Lomb division... More
Valeant Pharma (VRX) said still discussing possible sale of Bausch + Lomb - Fox News
April 8, 2016 12:30 PM EDTValeant Pharma (NYSE: VRX) said still discussing possible sale of Bausch + Lomb, according to Fox News.
Bankers tell @FoxBusiness... More
Valeant (VRX) Derm NRx Down 6% Week-Over-Week - RBC Capital
April 8, 2016 10:21 AM EDTRBC Capital analyst Douglas Miehm notes Valeant Pharmaceuticals (NYSE: VRX) Derm NRx (largely Walgreens) decreased 6.0% week over week. Meanwhile both ophth and Addyi Walgreens access programs were launched February 15th; ophth NRx were up 0.1% week-over-week and Addyi NRx were up 1.7% week-over-week.
Miehm commented, "For the week ending April 1st, new... More
UPDATE: Valeant Pharma (VRX) Said Actively Discussing Sale of Bausch + Lomb Unit
April 7, 2016 3:40 PM EDT(Updated - April 7, 2016 3:45 PM EDT)
Valeant Pharma (NYSE: VRX) said to be actively discussing the sale of its Bausch + Lomb unit, according to Fox News.
UPDATE - News comes from Fox's Charlie Gasparino today. The following was posted to... More
Valeant gets extra month to file annual report
April 7, 2016 7:55 AM EDT(Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) said on Thursday its lenders had agreed to give it an extra month to file its annual report, providing breathing room for the embattled drugmaker as it tries to win back investor confidence.
The extension provides relief if Valeant is unable to file its annual report by April 29 - a deadline the company reiterated it intended to meet. The company missed an original March 15 deadline, blaming an in-house review of its accounting practices.
Valeant last week said it risked defaulting on its $30 billion... More
Valeant Pharma (VRX) Announces Receipt of Lender Consent For Credit Facility Amendment
April 7, 2016 7:31 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that it has obtained the requisite lender approval for the amendment and waiver to its credit facility. The Company expects to close the amendment and waiver next week.
Pursuant to the approved waiver, the deadline for filing the Company's Form 10-K will be extended to May 31, 2016 and the deadline for filing its Form 10-Q for the quarter ended March 31, 2016 will be extended to July 31,... More
